In summary, we have identified that visfatin can trigger the EMT of CRC cells via Akt/GSK-3β/β-catenin signals and suggested that increased expression of visfatin resulted in a more aggressive phenotype in CRC patients. The gene discussed is NAMPT; the disease is colorectal carcinoma.